Endometrial cancer (EC) is the most common gynecological malignancy in developed countries, with a cumulative lifetime risk of 1.8 % [1]. Although the majority of patients are diagnosed at early stages, which are associated with a favorable prognosis (5-year overall survival rate of 76 %), accurate preoperative staging remains critical for guiding treatment decisions [2]. Key prognostic factors for EC include FIGO stage, histological type, tumor grade, depth of myometrial invasion, cervical invo…